CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 20 enrolled
Drug / intervention
Afrezza Inhalant Productdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03324776
NCT03324776Phase 3Completed
CompareCT.gov

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

Model Clinical Research LLC·interventional·Posted Oct 30, 2017·Updated Jun 26, 2024

In Brief

A Phase 3 clinical trial evaluating Afrezza Inhalant Product for Type2 Diabetes. Completed, enrolled 20 participants across 1 site.

Detailed Summary

To examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType2 Diabetes
CountriesUnited States
CollaboratorsMannkind Corporation

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedOct 30, 2017
Enrollment StartOct 16, 2017
Primary CompletionJun 10, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.7 years ago

Interventions

Afrezza Inhalant Productdrug

Mealtime Ultra-Rapid Acting Insulin